- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
2 Arrested in Samsung Bioepis Accounting Probe
On Monday, the Seoul Central District Prosecutor’s Office in the Republic of Korea arrested an executive and another employee at biosimilar developer Samsung Bioepis for falsifying and destroying evidence and for violating audit law.
According to the Financial Times and other sources, on Monday, the Seoul Central District Prosecutor’s Office in the Republic of Korea arrested an executive and another employee at biosimilar developer Samsung Bioepis for falsifying and destroying evidence and for violating audit law.
In November 2018, Korean regulators from the Securities and Futures Commission (SFC) said that, in 2015, Samsung BioLogics used accounting methods that allegedly misrepresented the value of the biosimilar maker prior to an initial public offering in 2016.
According to officials, Samsung BioLogics changed the way it accounted for its stake in Samsung Bioepis, a partnership with Biogen, by recognizing the partnership’s market value instead of its book value, thereby inflating its valuation.
According to Korea Biomedical Review, the arrest warrants that were executed this week are the first to be filed in the case and relate to data that may have been deleted from computers and mobile phones.
These data could be relevant, said officials, to determining whether Biogen’s contractual option to increase its share in the Samsung Bioepis partnership to 49.9% was hidden from accountants who were responsible for a merger between Cheil Industries and Samsung in 2015. Biogen announced in 2018 that it would exercise its option.
The arrests are the latest development in the probe that, last year, resulted in a $7.05 million fine, the suspension of Samsung BioLogics’ stock trading, and calls for the firing of the firm’s chief executive officer as well as the chief financial officer.
The company’s stock subsequently resumed trading in December 2018 after officials ruled that the company’s shares could remain listed while the case played out.
Then, in January of this year, a Korean court ruled that penalties against Samsung BioLogics should be suspended pending a final court determination on whether the company had indeed violated accounting standards.
For its part, Samsung BioLogics has maintained that it has not breached any accounting rules. In late 2018, the company launched an administrative lawsuit with the aim of proving the legality of its actions.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
